chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Started out with muscle weakness to legs, legs giving out when standing.  Then seizures started a few days after followed by inability to breathe on own.  Became vent. dependent.
Mom reports slight respiratory symptoms before bed on 11/14/15. Mom went to get him out of bed on 11/15/15 and he was in cardiopulmonary arrest. CPR was attempted with no improvement.
Red Spot; Red spot came back and it was itchy; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Red Spot) and PRURITUS (Red spot came back and it was itchy) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (Red Spot) and PRURITUS (Red spot came back and it was itchy). At the time of the report, ERYTHEMA (Red Spot) and PRURITUS (Red spot came back and it was itchy) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment related information has been reported.
hot flashes; Still not feeling great; chills; felt like he had COVID again/all the symptoms again; This spontaneous case was reported by a consumer and describes the occurrence of SUSPECTED COVID-19 (felt like he had Covid again/all the symptoms again), HOT FLUSH (hot flashes), VACCINATION COMPLICATION (Still not feeling great) and CHILLS (chills) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029A21A and 028A21A) for COVID-19 vaccination.   The patient's past medical history included COVID-19 in November 2020.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Apr-2021, the patient experienced SUSPECTED COVID-19 (felt like he had Covid again/all the symptoms again) and CHILLS (chills). On 05-Apr-2021, the patient experienced HOT FLUSH (hot flashes) and VACCINATION COMPLICATION (Still not feeling great). At the time of the report, SUSPECTED COVID-19 (felt like he had Covid again/all the symptoms again), HOT FLUSH (hot flashes), VACCINATION COMPLICATION (Still not feeling great) and CHILLS (chills) outcome was unknown.         No concomitant and treatment drugs were reported.   This case was linked to MOD-2021-067408 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 23-Jul-2021: Non significant follow-up, contains address of primary reporter.
pain, soreness at injection site for 36 hours; fatigue, body aches, moderate sinus headache for 36 hours.
Pyrexia. Information regarding Flumist (2003-2004 Formula) (influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a parent regarding his 5 year old son who received a dose in Dec 2003 and developed fever. The child's father reported that his son received a dose of Flumist (2003-4) in Dec-2003, and two days later, developed a fever (pyrexia) which has been "up and down" and as high as 102 degrees F. The child was seen by the physician but according to the father, his son did not have a fever that day. No additional information was available at the time of this report.
The patient experienced symptoms of throat swelling. These symptoms were Severe and were treated with epinephrine 0.3mg x 2 doses (1 in left upper arm and 1 in left thigh) and 50mg PO benadryl. The patient was discharged to ER after close observation for 20 minutes in improving condition.
Migraine  Nausea  Dehydration  Low grade fever  Fatigue
Minor fatigue side effect; This case was reported by a consumer via interactive digital media and described the occurrence of fatigue in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced fatigue. On an unknown date, the outcome of the fatigue was recovered/resolved.   It was unknown if the reporter considered the fatigue to be related to Shingles vaccine.     Linked case(s) involving the same patient:  US2022AMR017694  Additional details were provided as follows: The age at vaccination was not reported. The patient received dose of Shingles vaccine and experienced minor fatigue side effect. The follow-up would not possible, as no contact details were available. ; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR017694:Same reporter
On 10/25/99, pt recv'd Flu Shield & TD vax. That same day pt dvlped redness & swelling at injection site. He dvlped fever, chills, & sweats & was hospitalized on 10/28/99.Dx of cellulitis was made.
woke up with a rash; had a bad reaction initially; felt queasy but did not vomit; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE RASH (woke up with a rash), INJECTION SITE REACTION (had a bad reaction initially) and NAUSEA (felt queasy but did not vomit) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced INJECTION SITE REACTION (had a bad reaction initially) and NAUSEA (felt queasy but did not vomit). On 12-Mar-2021, the patient experienced INJECTION SITE RASH (woke up with a rash). At the time of the report, INJECTION SITE RASH (woke up with a rash), INJECTION SITE REACTION (had a bad reaction initially) and NAUSEA (felt queasy but did not vomit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Non significant follow up received on 15-JUN-2021, no new information
Slight fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Slight fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Slight fever). At the time of the report, PYREXIA (Slight fever) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information not reported. No concomitant medications reported.  Reporter (64 years old) stated patient is about 3 years older.  Full details were not obtained due to abrupt disconnection from call.
12noon-HA; 230PM devel rash & chills-rash on arms, chest, upper neck, top of legs-went to ER 330PM;-was told to go home & take DPH;
This spontaneous report was received from a medical assistant refers to an unspecified number of patients of unknown demographics. Patients medical history and concurrent conditions were not reported. On an unknown date, unspecified number of patients were vaccinated with COMVAX (dose, route of administration and anatomical location was unknown) that were improperly stored. Concurrent medications were unspecified by reporter. No adverse effects and product quality complaint was reported. The outcome of the events was unknown. No further informmation was provided. This is one of the several reports received from the same reporter. Additional information has been requested.
Onset of  nausea, vomiting, headache  15 min after the shot.  Then  approximately 4 to 6 hours after shot had  right leg weakness, pain and shooting pain numbness.  She had fever of 101 day 2.  Through Day  5 continued with nausea and headache but  vomiting subsided.  The  pain, numbness  has improved also after  2 to 3 days of  medrol dose  pack of steroids through neurology.  Swelling under  arm to axilla  per patient by day  2 was  baseball size and now decreased  to <  golf  ball size.   Patient contacted neurology after shot and  she was treated for MS  flare.  She also reports  now  in retrospect after Dose  #1 of covid 19 vaccine had  headache, nausea, fever for  several days after shot and then on Day #14 had eye blurriness she treated with medrol dose pack and sxs  subsided.  But she reports ongoing  daily headache since her  intial covid 19 vaccine.  She has been followed by her neurologist for above.
This spontaneous report was received from a certified medical assistant referring to unspecified patients of unknown age and gender. The patients' concurrent conditions and medical history were not provided. On unknown dates, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB lot #: K023863, expiration date on 03-APR-2016 and lot #: L045117, expiration date on 06-OCT-2018 (route, dose and anatomical location were not reported) which were stored in a temperature of 31F during 60 hours. Concomitant therapies were not provided. No adverse events were reported. No product quality complaint was involved. This is one of several reports coming from the same source. Additional information has been requested.
Sore injection site Body ache Chills Sustained heart rate greater than 120 BPM Lower back/hip ache Fatigue
After receiving last vaccine, she stated "I feel funny" (immediately after the injection). Eyes rolled back, head pulled to the right, body stiffened, legs jerking, unresponsive.  Lasted less than 1 minute.
Information has been received from a health professional concerning a pt who was vaccinated with pneumococcal vaccine 23 polyvalent. Subsequently, the pt experienced malaise, fever, nausea and vomiting, post vax. Unspecified medical attention was sough. No further information is available.
Received vaccination on 9/18/10 - the follow night began vomiting severe stomach pain/cramping/ distended week later has same symptoms. Had severe pressure at night. Developed bumps on (R) and (L) thighs. Bumps hard and sore to touch. Has had vaccination ever year. Husband received same vaccination at same time and is beginning to have same reaction. S/w pt on 9/25 and abd distention and large lymph nodes in lower extremities. Had doctors appointment did blood work, CT scan and possible MRI. Diagnosis of pancreatitis related to flu shot.
Expired dose administered (booster); This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired dose administered (booster)) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048L21A) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: J&J (First dose) on 12-Mar-2021. Past adverse reactions to the above products included No adverse event with J&J.    On 08-Mar-2022 at 9:45 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 08-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired dose administered (booster)). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired dose administered (booster)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided by the reporter.  No treatment details were provided.  Patient height  was reported as 5'6". It was reported that the dose was administered more than 12(US) hours post puncture. The vial was initially stored in the refrigerator on 07-Mar-2022 and vial was first punctured 07-Mar-2022 at 2:30 PM. Vaccine did not undergo any temperature excursions the vial was exposed to room temperature range (8 degree Celsius to 25 degree Celsius equal to 46 degree to 77 degree Fahrenheit) under 5 minutes per HCP.
At 1:00am I woke up out of a dead sleep to stomach pains. I had diarrhea about every 20 minutes along with dry heaving for about 4 hours. My arm was severely sore as well. I took two Tylenol PM pills and was able to sleep for a few hours before the stomach pain started again with dry heaving/diarrhea. Body aches, headache, and profusely sweating started about 6am. From about 8am-6pm I could not keep anything down as I was violently vomiting bile every 30minutes to an hour.  At about 6pm I was able to keep applesauce down and continued to feel better. The next day I just had slight nausea and was profusely sweating again. No known fever on any day.
anxiety; high blood pressure; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Nov-2021 and was forwarded to Moderna on 23-Nov-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ANXIETY (anxiety) and HYPERTENSION (high blood pressure) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced ANXIETY (anxiety) and HYPERTENSION (high blood pressure). At the time of the report, ANXIETY (anxiety) and HYPERTENSION (high blood pressure) had not resolved. Not Provided. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Blood pressure measurement: high (High) high. No treatment medication and concomitant medication was provided.
This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications information was reported.  It was reported that there have been no power outages that would have impacted the Moderna vaccine. However, reporter reiterated that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger that caller was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. Reporter said that they were filling out a temperature excursion assessment with the State at this time and she was calling in to report the same to Moderna. Reporter confirmed that patients have been administered doses while the temperature excursion assessment has been ongoing.  It was reported that no adverse reactions were reported by any patients.  No treatment information was provided.
TERRIBLE THING IN THE KNEECAP; This spontaneous report received from a patient concerned a patient of an unspecified age, sex, race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. On an unspecified date, the patient previously received covid-19 vaccine ad26. cov2.s (dose number in series 1) (unspecified manufacturer) (suspension for injection, route of admin not reported, batch number: unknown and expiry: unknown) dose was not reported,1 total administered for prophylactic vaccination. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient received covid-19 vaccine ad26.cov2.s (dose number in series 2) (unspecified manufacturer) (suspension for injection, route of admin not reported, batch number: unknown and expiry: unknown) dose was not reported, 1 total administered on 24-OCT-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 25-OCT-2021, following vaccination with covid-19 vaccine ad26.cov2.s, the patient had no pain in the arm but experienced terrible thing in the kneecap (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of terrible thing in the kneecap was not reported. This report was non-serious.
ADVERSE EVENT(s): Arm soreness and tiredness  ((As of August 12, 2021, I am still experiencing the following symptoms on and off)):  difficulty breathing (chest tightness), fast heartbeat, allergies/rash, dizziness, tiredness, brain fog, increased muscle/joint pain, chills, occasion fever, headache, and unexpected hormonal/mood changes. TREATMENT: Primary care doctor visits, self-care, meditation, podcasts, mental health awareness/seminars, excercise, rest, and a new neuorology, pain management specialist - medication management and changes. OUTCOME: TBD.
swollen lymph nodes around her left side of breast; her arm hurt so bad/worst pain; hard lump under left armpit; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (swollen lymph nodes around her left side of breast), VACCINATION SITE PAIN (her arm hurt so bad/worst pain) and VACCINATION SITE MASS (hard lump under left armpit) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to antibiotic (amoxicillin).    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Mar-2021, the patient experienced LYMPHADENOPATHY (swollen lymph nodes around her left side of breast), VACCINATION SITE PAIN (her arm hurt so bad/worst pain) and VACCINATION SITE MASS (hard lump under left armpit). The patient was treated with IBUPROFEN for Symptomatic treatment, at an unspecified dose and frequency. At the time of the report, LYMPHADENOPATHY (swollen lymph nodes around her left side of breast), VACCINATION SITE PAIN (her arm hurt so bad/worst pain) and VACCINATION SITE MASS (hard lump under left armpit) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) Negative-3 different times.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications was not provided by the reporter.
Body aches lasting 24-36 hours. Headache lasting 24 hours . Ringing in ears - still apparent 36 hours later.
Sore/stiff arm with small welt for 2 days following injection. 8 days post vaccination, splotchy, warm, red spot with occasional itchiness. 9 days post vaccination, splotchy, warm, red spot is slightly larger, welt developed overnight still just occasional itchiness
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2022 at 5:56 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 11-Feb-2022 at 5:56 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 11-Feb-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.   It was reported that, vaccine was administered on 11-Feb-2022 at 17:56:27.  No treatment details were reported.
Immediately after injection, patient lost palor in face. Reported felt fine and sat in waiting room for required post vaccine time observation. Became nauseated and ambulated toward bathroom. Vomited in hallway. Patient shaking, clammy, noted decrease in palor of face.
Pain in the injection site; Sore throat; Fatigue; Headache; Worsened tinnitus; dizziness; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the arm left on 23Apr2021 at 12:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included tinnitus, temporomandibular joint disorder and bipolar disorder. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included amoxicillin (MANUFACTURER UNKNOWN) for urinary tract infection from an unknown date and unknown if ongoing and ferrous sulfate/folic acid/zinc (PRENATAL) for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 the patient experienced pain in the injection site, sore throat, fatigue, headache, worsened tinnitus and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in the injection site, sore throat, fatigue, headache, worsened tinnitus and dizziness were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.